WO1995031979A1 - Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions - Google Patents

Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions Download PDF

Info

Publication number
WO1995031979A1
WO1995031979A1 PCT/US1995/006183 US9506183W WO9531979A1 WO 1995031979 A1 WO1995031979 A1 WO 1995031979A1 US 9506183 W US9506183 W US 9506183W WO 9531979 A1 WO9531979 A1 WO 9531979A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
ketoprofen
weight
pharmaceutical composition
formula
Prior art date
Application number
PCT/US1995/006183
Other languages
French (fr)
Inventor
Rickey S. Shelley
Youching Wei
Original Assignee
R.P. Scherer International Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US24702894A priority Critical
Priority to US08/247,028 priority
Application filed by R.P. Scherer International Corporation filed Critical R.P. Scherer International Corporation
Publication of WO1995031979A1 publication Critical patent/WO1995031979A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Abstract

Methods and compositions are disclosed for preparing liquid mixtures of aryl or heteroaryl alkanoic acids suitable for encapsulation in soft gelatin capsules. The compositions comprise alkanoic acids of formulas (I), (Ia), (Ib) or pharmaceutically acceptable salts thereof, wherein R, R1, R2, R3, and R5 represent hydrogen or various organic substituents, and an effective solubilizing amount of at least one lipophilic solvent.

Description

SOLUTIONS OF ARYL OR HETEROARYL SUBSTITUTED

ALKANOIC ACIDS IN LIPOPHILIC SOLVENTS AND

SORT GELATIN CAPSULES CONTAINING SUCH SOLUTIONS BACKGROUND OF THE INVENTION

Field of the Invation

The present invention relates to solutions containing therapeutically useful substituted alkanoic acids in combination with at least one lipophilic solvent for encapsulation in soft gelatin capsules (softgel capsules).

Description of the Related Art

Hydrophilic softgels are well known for the oral administration of pharmaceutical agents. Typically, softgel capsules consist of an outer shell bt gelatin containing a plaβticizer and an inner filling of hydrophilic liquid containing a dissolved hydrophobic pharmaceutical agent. The plasticizer is chosen so that the solubility in the fill liquid is as low as possible. If the plasticizer is soluble in the fill liquid, it can migrate out of the shell over time into the fill, leaving the shell brittle and subject to rupture.

With respect to pharmaceutical atøents of relatively low solubility and/or relatively high dosage amount, softgel capsules can pose problems for the pharmaceutical fonnulator. For example, if a given pharmaceutical agent has a relatively low solubility, it may need a relatively large volume of solution in order to deliver a pharmaceutically acceptable unit dose. While theoretically possible to encapsulate such a large volume of solution in a softgel capsule, for example, the practical limitations on the size of capsules suitable for conventional oral administration to human patierits could well preclude pharmaceutical use of the resulting softgel.

Similarly, if a pharmaceutical agent requires a relatively high dose, a large volume of solution may again be a necessity for delivery of the require dosage. Softgel encapsulation of such a large solution volume may be impractical because the size of the needed softgel would likely exceed the maximum limit for conventional oral administration to huiaan patients.

As one approach to handling the problems of encapsulating low solubility or high dose pharmaceutical agents, U.S. Patent No. 5,071,643 (Yu et. al.) discloses the use of polyethylene glycol based solutions for acidic, basic and amphoteric pharmaceutical agents. These polyethylene glycol based solutions contain either an hydroxide species or a hydrogen ion species that causes the appropriate pharmaceutical agent to partially ionize, i.e., the pharmaceutical agent is present in both the free form and the salt form. The partial ionization described in Yu et al. results in enhanced solubillity for the acidic, basic or amphoteric pharmaceutical agent. This enhanced solubility, in turn, nay permit the preparation of a solution of pharmaceutical agent that is highly concentrated enough to be encapsulated in a capsule acceptably sized for oral administration to human patients. The Yu et al. patent discloses that enhanced solubility solutions can be prepared using polyethylene glycol and contemplated ecnaivalents of polyethylene glycol, such as polyethylene glycol eφhers or various alcohols and copolymers of polyethylene glycol.

Softgel encapsulation is sometimes the preferred delivery system for many pharmaceutical agents that are administered orally to human patients. Generally, to be suitable for softgel encapsulation, a pharmaceutical formulation should be in the form of a clear, stable solution. The present inventors have discovered that the enhanced solubility solutions disclosed by the Yu et al. patent are not as effective with various substituted alkanoic acid pharmaceutical agents.

Therapeutically useful 2- or 3-aryl or 2- or 3-heteroaryl substituted alkanoic acids function as anti-inflammatory and analgesic agents and may be administered orally. They are also essentially insoluble in water. An example of such a useful alkanoic acid suitable for use in the present invention is ketoprofen which is 2-(3-benzoylphenyl) propionic acid.

Ketoprofen is an anti-inflammatory, analgesic agent that is principally indicated for the acute and long-term management of rheumatoid arthritis and osteoarthritils. Additionally it is a nonsteroidal compound and poorly water soluble. Some gastrointestinal irritation is ordinarily associated with oral doβage forms of ketoprofen. The properties of ketoprofen render it a good candidate for formulation with the enhanced solubility solutions disclosed in the Yu et al. patent. In a number of experiments, the present inventors applied the Yu et al. enhanced solubility solutions in formulations of ketoprofen for softgel encapsulation. In one formulation, polyethylene glycol 400 and potassium hydroxide were used to solubilize the ketoprofen, with the mole ratio of potassium hydroxide to ketoprofen being in the range of 0.4 to 1. It was surprisingly found that the resulting formulation was not sufficiently stable for softgel encapsulation due to the undesirable formation of ketoprofen esters.

In an attempt to completely ionize the ketoprofen to prevent the formation of undesirable esters, the potassium hydroxide to ketoprofen mole ratio was adjusted to range from 1.1 to 1. With this second formulation, concerns arose that the ketoprofen salt thus formed and/or the high pH caused by the excess potassium hydroxide used could affect the physical stability of the softgel capsule when the formulation was encapsulated. Additionally, if an equilibrium amount of the ketoprofen Ifree acid remained in the solution, it could form ketoprofen esters that could drive the reaction to form more ketoprofen free acid species, which could eventually result in a chemically unstable formulation.

The present inventors have discovered that non-hydroxyl containing solvents may be used to form pharmaceutically acceptable solutions of 2- or 3-aryl or 3-heteroaryl substituted alkanoic acids that are stable and suitable for softgel encapsulation. SUMMARY OF THE INVENTION

The present invention provides enhanced solubility pharmaceutically acceptable solutions of therapeutically useful substituted alkanoic acids, preferably 2- or 3-aryl or 2- or 3- heteroaryl alkanoic acids, that can be encapsulated in softgel capsules of a size suitable for subsequent oral administration to human patients, having improved chemical stability compared with polyethylene glycol water miscible formulations of the alkanoic acids.

The therapeutically useful active agents, i.e., substituted alkanoic acids, preferred for use in the present invention have general formulas I, la or lb:

Figure imgf000007_0001

or pharmaceutically acceptable salts thereof, wherein

R represents a hydrogen atom or an alkyl group containing

1 to 4 carbon atoms;

R1 represents hydrogen, halogen, C1-C8 alkyl, phenylalkyl where the alkyl is C1-C6 alkyl, a benzoyl group of the formula:

Figure imgf000007_0002
where R4 represents hydrogen, C1-C6 alkyl, or an alkylthio group having 1 to 4 carbon atoms; or

R1 represents a group of the formula:

Figure imgf000008_0001
where n is 0, 1 or 2;

R2 represents hydrogen, hydroxy or C1-C6 alkoxy;

R3 represents hydrogen, C1-C6 alkyl or phenyl; and

R5 is C1-C6 alkoxy.

The enhanced solubility pharmaceutically acceptable solutions of therapeutically useful alkanoic acids can be encapsulated in softgel capsules of a size suitable for subsequent oral administration to human patients, which improves the physical stability of the softgel capsules used to encapsulate the pharmaceutical solutions compared with polyethylene glycol water miscible formulations of the alkanoic acids.

The present invention also provides enhanced solubility pharmaceutically acceptable solutions of alkanoic acids that unexpectedly can be encapsulated in a softgel capsule of a size smaller than what is required to encapsulate the same dose of the acid in polyethylene glycol water miscible formulations.

The enhanced solubility pharmaceutically acceptable solutions of 2- or 3-aryl or 3-heteroaryl alkanoic acids provided by the present invention may reduce or eliminate the gastrointestinal irritation associated with oral dosage forms of these agents.

The lipophilic solvent and the hydroxyl containing softgel capsule plasticizers, such as glycerin, are immiscible, thereby improving both the chemical stability of the acid solution and improving the physical stability of the softgel capsule by greatly reducing the migration of capsule plasticizers into the encapsulated pharmaceutical formulation. Additionally, the use of the lipophilic solvent prevents the formation of esters which can decrease the chemical stability of the alkanoic acid solution.

Suitable lipophilic solvents are polyol esters of fatty acids. The polyol esters of fatty acids may be mono-, di-, tri-, etc, esters of the polyols. Thus, thare may be free hydroxyl groups present in the polyol esters of fatty acids useful as lipophilic solvents of the invention.

The lipophilic solvent preferred for use in the present invention is an alkylene glycol derivative of formula II:

Figure imgf000009_0001

wherein

A represents C1-C4 alkylene optionally substituted with alkyl or a group of the formula and

Figure imgf000010_0001

the R" groups are the same of different and represent C1-C12 alkyl.

Further objects and embodiments of the present invention will be described in the following description of the preferred embodiments.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is useful for providing pharmaceutically acceptable solutions of substituted alkanoic acids dissolved in at least one lipophilic solvent, which are chemically stable and suitable for softgel encapsulation.

The therapeutically useful active agents, I.e., substituted alkanoic acids, preferred for use in the present invention have general formulas I, la or lb:

Figure imgf000011_0001

or pharmaceutically acceptable salts thereof,

wherein

R represents a hydrogen atom or an alkyl group containing

1 to 4 carbon atoms;

R1 represents hydrogen, halogen, C1-C6 alkyl, phenylalkyl where the alkyl is C1-C6 alkyl, a benzoyl group of the formula:

Figure imgf000011_0002
where R4 represents hydrogen, C1-C6 alkyl, or an alkylthio group having 1 to 4 carbon atoms; or R1 represents a group of the formula:

Figure imgf000012_0001
where n is 0, 1 or 2;

R2 represents hydrogen, hydroxy or C1-C6 alkoxy;

R3 represents hydrogen, C1-C6 alkyl or phenyl; and

R5 is C1-C6 alkoxy.

Suitable pharmaceutically acceptable, non-toxic salts include salts such as, for example, alkali metal, alkaline earth metal, ammonium and amine salts. Compounds of general formulas I, la, and lb in which R represents an alkyl group can exist in optically active forms, including isomers and racemates thereof. Preferred alkanoic acids suitable for use in the present invention include ketoprofen (formula l where R is methyl, R1 is benzoyl, and R1 and R3 are hydrogen, i.e.. 2-(3- benzoylphenyl)propionic acid); ibuprofen (formula I where R is methyl, R1 and R2 are hydrogen, and R3 is isobutyl, i.e., 2-(4- isobutylphenyl)propionic acid); naproxen (formula la where R is methyl and R5 is methoxy, i.e., 2-(6-methoxy naphthyl)propionic acid); and oxaprozin, (formula lb, i.e., 4,5-diphenyl-2- oxazolepropionic acid).

The enhanced solubility pharmaceutically acceptable solutions of therapeutically useful substituted alkanoic acids can be encapsulated in softgel capsules of a size suitable for eubsequent oral administration to human patients, which improves the physical stability of the softgel capsules used to encapsulate the pharmaceutical solutions compared with polyethylene glycol water miscible formulations of the alkanoic acids.

The present invention also provides enhanced solubility pharmaceutically acceptable solutions of ketoprofen that can be encapsulated in a softgel capsule of a size smaller than what is required to encapsulate the same dose of the acids in polyethylene glycol water miscible formulations.

The present invention provides pharmaceutically acceptable solutions containing from about 0.1 to 1000 mg, preferably about 5 to 200 mg, and most preferably about 10 to 100 mg, of an alkanoic acid dissolved in at least one lipophilic solvent, resulting in a clear solution suitable for softgel encapsulation. The lipophilic solvent and the hydroxyl containing softgel capsule plasticizers, such as glycerin, are immiscible, thereby improving both the chemical stability of the alkanoic acid solution and improving the physical stability of the softgel capsule by greatly reducing the migration of capsule plasticizers into the encapsulated pharmaceutical formulation. Additionally, the use of the lipophilic solvent prevents the formation of esters which can decrease the chemical stability of the alkanoic acid solution.

Suitable lipophilic solvents are polyol esters of fatty acids. The polyol esters of fatty acids may be mono-, di-, tri-, etc, esters of the polyols. Thus, there may be free hydroxyl groups present in the polyol esters of fatty acids useful as lipophilic solvents of the invention.

The lipophilic solvent preferred for use in the present invention is an alkylene glycol derivative of formula II:

wherein

Figure imgf000014_0001
A represents C1-C4 alkylene optionally substituted with alkyl or and

Figure imgf000014_0004

the R" groups are the same or different and represent C1-C12 alkyl.

Suitable lipophilic solvents include those of formula III:

Figure imgf000014_0002
where the R" groups are the same or different and represent C1-

C12 alkyl and R''' is hydrogen or

Figure imgf000014_0003
Suitable lipophilic solvents also include those of formula IV:

Figure imgf000015_0002
where the RH groups are the same or different and represent C1- C12 alkyl and R' is C1-C6 alkyl.

Other suitable lipophilic solvents are those of formula III where the R" groups are the same and represent C1-C4 alkyl and R''' is

Figure imgf000015_0001

Still other suitable lipophilic solvents are those of formula IV where the R" groups are the same or different and represent C1-C4 alkyl and R' is methyl.

Most preferred lipophilic solvents of formula III are those where R" is methyl. Most preferred lipophilic solvents of formula IV are those where the R" groups are the βarne or different and represent CH3(CH2)6 or CH3(CH2)8.

Particularly preferred solvents are selected from the group consisting of propylene glycol dicaprylate/dicaprate, 1,2,3- propanetriol triacetate and mixtures thereof. Most preferably the solvents suitable for use in the present invention include propylβne glycol dicaprylate/dicapxfate, 1,2,3-propanetriol triacetate and mixtures thereof. Propylene glycol dicaprylate/dicaprate is available under the trade name Captex 200 from Karlshamn Lipid Specialties and 1,2,3-propanetriol triacetate is available under the trade name Triacetin from Eastman Chemicals.

The inventive solutions may also contain optional, additional ingredients to improve the dispersivity and dissolution of the substituted alkanoic acid. Suitable additional components include surfactants such as, for example, polyglyceryl esters of fatty acids, polyglycolyzed glycerides, propylene glycol esters, mono- and di-glycerides, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbitol esters, polyoxyethylene adds, polyoxyethylene alcohols, and mixtures thereof. A preferred class of surfactants for use in combination with the lipophilic βolvents is the polyoxyethylene sorbitan fatty acid esters. Suitable sorbitan esters are sold under the trade name Tween. A particularly useful Tween is polyoxyethylene (20) sorbitan mono-oleate (Tween 80).

The active substituted alkanoic acid pharmaceutical agent may be present in the solution in amounts ranging up to about 30% by weight of the solution. Preferred concentrations of the active agent are from about 5-20%, more preferably about 10-15%, by weight of the final solution. Combinations of lipophilic solvents may be used to obtain a desired final concentration. For example, ketoprofen may be present in the solution in amounts ranging up to about 5% by weight of the solution when dissolved only in propylene glycol dicaprylate/dicapratβ. Ketoprofen may be present in the solution in amounts ranging up to about 14% by weight of the solution when dissolved only in 1,2,3-propanetriol triacetate. When dissolved In a mixture of propylene glycol dicaprylate/dicaprate, 1,2,3-propanβtriol triacetate and Tween, the ketoprofen pharmaceutical agent may be present in solution in amounts ranging Up to about 22% by weight of solution.

In addition to the ketoprofen pharmaceutical agent and the lipophilic solvents, other adjuncts may optionally be present.

Polyoxyethylene (20) sorbitan mono-oleate (Tween 80) may be included in the solution up to about 50% by weight of the solution.

Once the appropriate pharmaceutically acceptable solution of the substituted alkanoic acid is formulated, it can be encapsulated into conventional softgel capsules using any suitable encapsulation method, such as for example, the rotary die process.

All documents, e.g., patents and journal articles, cited above or below are hereby incorporated by reference in their entirety.

One skilled in the art will recognize that modifications may be made in the present invention without deviating from the spirit or scope of the invention. The invention is illustrated further by the following examples which are not to be construed as limiting the invention or scope of the specific procedures described herein.

Example 1

Pharmaceutically acceptable solutions containing ketoprofen are prepared in the following manner. First, mix the following until homogeneous:

(1) about 92 mg of propylene glycol dicaprylate/dicaprate;

(2) about 92mg of 1,2,3-propanetriol acetate; and

(3) about 10 mg of polyoxyethylene (20) sorbitan mono- oleate.

Second, add about 25 mg of ketoprofen to the homogeneous mixture of propylene glycol dicaprylate, 1,2,3-propanetriol acetate and polyoxyethylene (20) sorbitan mono-oleate, and mix again. While mixing in the ketoprofen, heat the mixture and maintain the temperature between 110-125°F until the ketoprofen is dissolved. Once the ketoprofen is fully dissolved, the solution is then cooled and deaerated. After being cooled and deaerated, the ketoprofen solution can be encapsulated in suitable softgel capsules, such as 4 oval softgel. The filled softgel capsules are thereafter dry finished to the appropriate hardness.

Example 2

Pharmaceutically acceptable solutions containing ketoprofen are prepared in the following manner. First, mix the following until homogeneous: (1) about 112 mg of propylene glycol dicaprylate/dicaprate;

(2) about 72 mg of 1,2,3-propanetriol acetate; and

(3) about 14 mg of polyoxyethylene (20) sorbitan mono- oleate.

Second, add about 25 mg of ketoprofen tlo the homogeneous mixture of propylene glycol dicaprylate, 1,2,3-propanetriol acetate and polyoxyethylene (20) sorbitan mono-oleate, and mix again. While mixing in the ketoprofen, heat the mixture and maintain the temperature between 110-125°F until the ketoprofen is dissolved. Once the ketoprofen is fully dissolved, the solution is then cooled and deaerated. After being cooled and deaerated, the ketoprofen solution can be encapsulated in suitable softgel capsules, such as 4 oval softgel. The filled softgel capsules are thereafter dry finished to the appropriate hardness.

Example 3

Pharmaceutically acceptable solutions containing up to about 22% ketoprofen by weight of solution are prepared in the following manner, which provides a self-emulsifying system. First, mix the following until homogeneous:

(1) propylene glycol dicaprylate/dicaprate in an amount ranging from about 40% to about 98% by weight;

(2) 1,2,3-ρropanβtriol acetate in an amount ranging from about 1% to about 55% by weight; and

(3) polyoxyethylene (20) sorbitan mono-oleate in an amount ranging from about 1% to about 50% by weight. Second, add ketoprofen to the homogeneous mixture of propylene glycol dicaprylate, 1,2,3-propanetriol triacetate and polyoxyethylene (20) sorbitan mono-oleate, and mix again. While mixing in the ketoprofen, heat the mixture and maintain the temperature between 110-125°F until the ketoprofen is dissolved.

Once the ketoprofen is fully dissolved, the solution is then cooled and deaerated. After being cooled and deaerated, the ketoprofen solution can be encapsulated in suitable softgel capsules. The filled softgel capsules are thereafter dry finished to the appropriate hardness.

Example 4

Pharmaceutically acceptable solutions containing up to about 14% ketoprofen by weight of solution are prepared in the following manner. First, mix the following until homogeneous:

(1) propylene glycol dicaprylate/dicaprate in an amount ranging from about 1% to about 50% by weight; and

(2) 1,2,3-propanetriol acetate in an amount ranging from about 50% to about 99% by weight.

Second, add ketoprofen to the homogeneous mixture of propylene glycol dicaprylate and 1,2,3-propanetriol acetate and mix again. While mixing in the ketoprofen, heat the mixture and maintain the temperature between 110-125°F until the ketoprofen is dissolved. Once the ketoprofen is fully dissolved, the solution is then cooled and deaerated. After being cooled and deaerated, the ketoprofen solution can be encapsulated in suitable softgel capsules. The filled softgel capsujles are thereafter dry finished to the appropriate hardness.

Example 5

Pharmaceutically acceptable solutions containing up to about 5% ketoprofen by weight of solution are prepared by mixing the ketoprofen with propylene glycol dicaprylate/dicaprate while heating the mixture. The temperature of the mixture should be maintained between 110-125°F until the ketoprofen is dissolved. Once the ketoprofen is fully dissolved, the solution is then cooled and deaerated. After being cooled and deaerated, the ketoprofen solution can be encapsulated in suitable softgel capsules. The filled softgel capeules are thereafter dry finished to the appropriate hardness.

Example 6

Pharmaceutically acceptable solutions containing up to about 14% ketoprofen by weight of solution are prepared by mixing the ketoprofen with 1,2,3-propanetriol acetate while heating the mixture. The temperature of the mixture should be maintained between 110-125°F until the ketoprofen is dissolved. Once the ketoprofen is fully dissolved, the solution is then cooled and deaerated. After being cooled and deaerated, the ketoprofen solution can be encapsulated in suitable softgel capsules. The filled softgel capsules are thereafter dry finished to the appropriate hardness. Example 7

The following formulations are prepared according to the invention using the procedure set fortth above in Example 1.

Figure imgf000022_0002

Example 8

The following comparative formulations are prepared essentially as in the procedure set forth above in Example 1 but do not include the lipophilic solvent according to the invention.

Figure imgf000022_0001

Certain specific embodiments of the present invention have been discussed and disclosed in detail. Many other embodiments that have not been disclosed or described are nevertheless the equivalent of and fall within the scope of the present invention and/or the following claims.

Claims

WE CLAIM :
1. A pharmaceutical composition comprising alkanoic acids selected from the group consisting of alkanoic acids of the formulas:
Figure imgf000024_0001
or pharmaceutically acceptable salts thereof,
wherein
R represents a hydrogen atom or aln alkyl group containing
1 to 4 carbon atoms;
R1 represents hydrogen, halogen, C1-C6 alkyl, phenylalkyl where the alkyl is C1-C6 alkyl, a benzoyl group of the formula:
Figure imgf000024_0002
where R4 represents hydrogen, C1-C6 alkyl, or an alkylthio group having 1 to 4 carbon atoms; or
R1 represents a group of the formula:
Figure imgf000025_0001
where n is 0, 1 or 2;
R2 represents hydrogen, hydroxy or C1-C6 alkoxy;
R3 represents hydrogen, C1-C6 alkyl or phenyl; and
R5 is C1-C6 alkoxy.
the 2-phenyl or naphthyl alkanoic acid being solubilized in a lipophilic solvent.
2. A pharmaceutical composition according to Claim 1 wherein the lipophilic solvent has the formula:
Figure imgf000025_0002
wherein
A represents C1-C4 alkylene optionally substituted with alkyl or and
Figure imgf000025_0003
the R" groups are the same of different and represent C1-C12 alkyl.
3. A pharmaceutical composition according to Claim 1 wherein the lipophilic solvent has the formula:
Figure imgf000026_0004
where the R" groups are the same or different and represent C1- C12 alkyl and R''' is hydrogen or
Figure imgf000026_0001
4. A pharmaceutical composition according to Claim 1 wherein the lipophilic solvent has the formula:
Figure imgf000026_0002
where the R" groups are the same or different and represent C1- C12 alkyl and R' is C1-C6 alkyl.
5. A pharmaceutical composition according to Claim 3, where the R" groups are the same and represent C1-C4 alkyl and R''' is
Figure imgf000026_0003
6. A pharmaceutical composition accoriding to Claim 4, where the R" groups are the same or different and represent C1-C4 alkyl and R' is methyl.
7. A pharmaceutical composition accoriding to claim 1, wherein the lipophilic solvent comprises a mixture of a alkylene glycol derivative of the formula:
Figure imgf000027_0001
where the R" groups are the same or different and represent C1- C12 alkyl and R''' is hydrogen or and
Figure imgf000027_0002
a alkylene glycol derivative of the formula:
Figure imgf000027_0003
where the R" groups are the same or different and represent C1- C12 alkyl and R' is C1-C6 alkyl.
8. A pharmaceutical composition! of Claim 1 wherein at least one lipophilic solvent has no free hydroxy1 groups.
9. A pharmaceutical composition comprising ketoprofen, naproxen, oxaprozin or ibuprofen solubilized up to 14% by weight in 1,2,3-propanetriol triacetate.
10. A pharmaceutical composition comprising ketoprofen, ibuprofen, oxaprozin or naproxen solubilized up to 5% by weight in propylene glycol dicaprylatβ/dicaprate.
11. The pharmaceutical composition of claim 9, wherein the ketoprofen, naproxen, oxaprozin or ibuprofen is solubilized in a mixture of 1 to 50% by weight of propylene glycol dicaprylate/dicaprata and 50 to 99% by weight of 1,2,3- propanetriol triacetate.
12. A pharmaceutical composition comprising ketoprofen, oxaprozin, naproxen, oxaprozin or ibuprcjfen solubilized up to 22% by weight in a mixture of 40 to 98% by weight of propylene glycol dicaprylate/dicaprate, 1 to 55% by weight of 1,2,3-propanetriol triacetate, and 1 to 50% by weight of a surfactant.
13. A solution comprising from about 0.1 to about 30% by weight of Ibuprofen, naproxen, oxaprozin or ketoprofen in a lipophilic solvent.
14. A solution according to Claim 13, comprising from about 5 to about 20% by weight of ibuprofen, naproxen, oxaprozin or ketoprofen in a lipophilic solvent.
15. A solution according to Claim 13, comprising from about 10 to about 15% by weight of ibuprofen!, naproxen, oxaprozin or ketoprofen in a lipophilic solvent.
16. A soft gelatin capsule comprising a solution of ketoprofen, naproxen, or ibuprofen in 4 lipophilic solvent.
17. A soft gelatin capsule according to claim 16, wherein the amount of ketoprofen, naproxen, oxaprozin or ibuprofen in the solution is from about 10 to 15% by weight of the solution.
18. A solution according to Claim 13, wherein the lipophilic solvent is suitable for encapsulation by a gelatin shell.
19. A pharmaceutical composition comprising an amount of ketoprofen, ibuprofen, oxaprozin or naproxen effective to produce analgesia in a patient, the ketoprofen, ibuprofen, oxaprozin or naproxen being present as a solution in a pharmaceutically acceptable lipophilic solvent.
20. A method for preparing a liquid mixture of a 2- or 3- aryl or 3-heteroaryl alkanoic acid suitable for encapsulation in a soft gelatin capsule comprising mixing a 2- or 3-aryl or 3- heteroaryl alkanoic acid of the formula:
Figure imgf000030_0001
or pharmaceutically acceptable salts thereof,
wherein
R represents a hydrogen atom or an alkyl group containing
1 to 4 carbon atoms;
R1 represents hydrogen, halogen, C1-C6 alkyl, phenylalkyl where the alkyl is C1-C6 alkyl, a benzoyl group of the formula:
Figure imgf000030_0002
where R4 represents hydrogen, C1-C8 alkyl, or an alkylthio group having 1 to 4 carbon atoms; or
R1 represents a group of the formula:
Figure imgf000030_0003
where n is 0, 1 or 2;
R2 represents hydrogen, hydroxy or C1-C6 alkoxy;
R3 represents hydrogen, C1-C8 alkyl or phenyl; and R5 is C1-C6 alkoxy,
with an effective solubilizing amount of at Ieast one lipophilic solvent of the formula: o
Figure imgf000031_0002
wherein
A represents C1-C4 alkylene optionally substituted with alkyl or
and
Figure imgf000031_0001
the R" groups are the same of different and represent C1-C12 alkyl.
PCT/US1995/006183 1994-05-19 1995-05-19 Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions WO1995031979A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US24702894A true 1994-05-19 1994-05-19
US08/247,028 1994-05-19

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU25170/95A AU2517095A (en) 1994-05-19 1995-05-19 Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions

Publications (1)

Publication Number Publication Date
WO1995031979A1 true WO1995031979A1 (en) 1995-11-30

Family

ID=22933249

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/006183 WO1995031979A1 (en) 1994-05-19 1995-05-19 Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions

Country Status (2)

Country Link
AU (1) AU2517095A (en)
WO (1) WO1995031979A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962931B2 (en) 2001-06-21 2005-11-08 Pfizer Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
WO2006096580A1 (en) * 2005-03-08 2006-09-14 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US8933023B2 (en) 2004-03-12 2015-01-13 Biodel Inc. Rapid acting injectable insulin compositions
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9346766B2 (en) 2004-08-20 2016-05-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727109A (en) * 1985-01-04 1988-02-23 R. P. Scherer Corporation Pharmaceutical preparation with an active substance of low solubility in water and gastric juices
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
WO1992008445A1 (en) * 1990-11-13 1992-05-29 Affinity Biotech, Inc. Non-aqueous microemulsion for drug delivery
WO1992010996A1 (en) * 1990-12-18 1992-07-09 Merrell Dow Pharmaceuticals Inc. Enhanced bioavailability pharmaceutical composition containing probucol
WO1994007488A1 (en) * 1992-10-07 1994-04-14 Pfizer Inc. 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727109A (en) * 1985-01-04 1988-02-23 R. P. Scherer Corporation Pharmaceutical preparation with an active substance of low solubility in water and gastric juices
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
WO1992008445A1 (en) * 1990-11-13 1992-05-29 Affinity Biotech, Inc. Non-aqueous microemulsion for drug delivery
WO1992010996A1 (en) * 1990-12-18 1992-07-09 Merrell Dow Pharmaceuticals Inc. Enhanced bioavailability pharmaceutical composition containing probucol
WO1994007488A1 (en) * 1992-10-07 1994-04-14 Pfizer Inc. 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801925B2 (en) 1999-06-29 2017-10-31 Mannkind Corporation Potentiation of glucose elimination
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6962931B2 (en) 2001-06-21 2005-11-08 Pfizer Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US8933023B2 (en) 2004-03-12 2015-01-13 Biodel Inc. Rapid acting injectable insulin compositions
US9346766B2 (en) 2004-08-20 2016-05-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US10130685B2 (en) 2004-08-23 2018-11-20 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US10028925B2 (en) 2005-03-08 2018-07-24 Patheon Softgels, Inc. Liquid dosage forms of sodium naproxen
US10022344B2 (en) 2005-03-08 2018-07-17 Patheon Softgels, Inc. Liquid dosage forms of sodium naproxen
CN101166520B (en) 2005-03-08 2013-01-09 班纳制药公司 Solvent system for enhancing the solubility of pharmaceutical agents
WO2006096580A1 (en) * 2005-03-08 2006-09-14 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US9693979B2 (en) 2005-03-08 2017-07-04 Banner Life Sciences Llc Liquid dosage forms of sodium naproxen
US9693978B2 (en) 2005-03-08 2017-07-04 Banner Life Sciences Llc Solvent system for enhancing the solubility of pharmaceutical agents
EP3061447A1 (en) * 2005-03-08 2016-08-31 Banner Life Sciences LLC Solvent system for enhancing the solubility of pharmaceutical agents
US9717689B2 (en) 2005-09-14 2017-08-01 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9446001B2 (en) 2005-09-14 2016-09-20 Mannkind Corporation Increasing drug affinity for crystalline microparticle surfaces
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US10143655B2 (en) 2005-09-14 2018-12-04 Mannkind Corporation Method of drug formulation
US10130581B2 (en) 2006-02-22 2018-11-20 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US9446133B2 (en) 2008-06-13 2016-09-20 Mannkind Corporation Dry powder inhaler and system for drug delivery
US10201672B2 (en) 2008-06-13 2019-02-12 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9339615B2 (en) 2008-06-13 2016-05-17 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9511198B2 (en) 2008-06-13 2016-12-06 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US10172850B2 (en) 2008-12-29 2019-01-08 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9655850B2 (en) 2008-12-29 2017-05-23 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US10130709B2 (en) 2011-06-17 2018-11-20 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9610351B2 (en) 2011-10-24 2017-04-04 Mannkind Corporation Methods and compositions for treating pain
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US10258664B2 (en) 2011-10-24 2019-04-16 Mannkind Corporation Methods and compositions for treating pain
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin

Also Published As

Publication number Publication date
AU2517095A (en) 1995-12-18

Similar Documents

Publication Publication Date Title
KR930000861B1 (en) Omeprazole rectal composition
RU2110257C1 (en) Pharmaceutical composition showing antifungal effect
EP0712631B1 (en) Cyclosporin containing multiple emulsions
JP3121080B2 (en) Solution for encapsulation
CA1165689A (en) Method of increasing oral absorption of polar bioactive agents
CA2159580C (en) Pharmaceutical compositions containing polyvinylpyrrolidone and a tri-ester and process of manufacture thereof
US4832957A (en) Controlled release combination of carbidopa/levodopa
EP0804170B1 (en) Method for making freeze dried drug dosage forms
ES2360102T3 (en) System for the controlled release of morphine.
DE60309433T2 (en) Pharmaceutical compositions for protease inhibitors for Hepatitis C virus
AU602677B2 (en) New pharmaceutical preparations with extended release
EP0293406B1 (en) Solvent system for an ionizable pharmaceutical agent
US5814332A (en) Procedure for encapsulating ibuprofen
US6383471B1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US4798725A (en) Sustained release capsule
US5980942A (en) Zero-order sustained release matrix tablet formulations of carbamazepine
US6524615B2 (en) Controlled release pharmaceutical composition
US4727109A (en) Pharmaceutical preparation with an active substance of low solubility in water and gastric juices
JP2568230B2 (en) Sufueroido
RU2216323C2 (en) Antifungal composition for oral administration comprising itraconazole and method for its preparing
EP0977562B1 (en) Methods and compositions for delivery of taxanes
CA1318600C (en) Sustained release etodolac
JP2559785B2 (en) Delayed release drug and its manufacturing method of the active ingredient
EP0678019B1 (en) Enhanced solubility pharmaceutical solutions
US6106864A (en) Pharmaceutical formulations containing darifenacin

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA